Appearance
Executive Summary
224 PowerGlide adverse events in FDA MAUDE. 34.1% of extracted failures are mechanical -- catheter shearing, guidewire kinking, tip separation during insertion (n=132 extracted). 30.3% are attributed to manufacturing defects. Stiletto's guidewire-free design eliminates the insertion mechanism responsible for the mechanical failures.
This report uses FDA MAUDE data to analyze BD's competitive vulnerability and position Stiletto as the safety-first alternative. The data is real, the limitations are stated clearly, and every claim includes its sample size.
What the Data Shows
| Finding | Value | Sample Size | Confidence |
|---|---|---|---|
| PowerGlide events | 224 total | n=224 events | High -- comprehensive |
| PowerGlide mechanical failures | 34.1% | n=132 extracted events | Moderate -- 58.9% extraction |
| Manufacturing defect root cause | 30.3% | n=132 extracted events | Moderate -- emerging signal |
| User error blamed vs justified | 49.2% blamed, 42.4% justified | n=132 extracted events | Moderate -- small unjustified gap (9 events) |
| Stiletto design advantage | Eliminates guidewire mechanism | Engineering analysis | High -- no wire = no wire failure |
| Market size (extended dwell midline) | $1.3-3.2B globally | Industry reports | Moderate -- range reflects methodology differences |
| BD mini-midline share | ~70% | Industry estimates | High |
What the Data Doesn't Show
- Absolute safety comparison -- BD has ~70% mini-midline share; Stiletto has <5%. More devices in field = more events reported. Raw event counts are not comparable.
- Real complication rates -- MAUDE captures 1-10% of actual events. We see patterns, not prevalence.
- Stiletto failure modes -- With <5% market share and limited time on market, absence of events is expected, not proof of perfection.
- True procedure-normalized rates -- Without knowing total PowerGlide insertions, we can't calculate failures per 1,000 procedures.
The Competitive Opportunity
BD dominates on distribution, GPO contracts, and sales force. They are vulnerable on insertion mechanism design. The argument is not "BD has more events than Stiletto" (that's market share). The argument is:
- BD's data shows two distinct problems -- 34.1% mechanical failures (insertion mechanism) and 30.3% manufacturing defects (production quality) across 224 PowerGlide events
- User error is real but not the whole story -- 49.2% blamed on users, but only 42.4% justified. A small unjustified blame gap (9 events) is emerging. And 30.3% manufacturing defects can't be blamed on technique.
- Stiletto removes the insertion mechanism -- guidewire-free design eliminates the mechanical failure mode entirely. No guidewire = no guidewire kink. No needle bevel interaction = no catheter shearing.
- The design advantage is error-proofing -- not a claim that clinicians are incompetent, but that good engineering prevents technique errors from causing patient harm. Manufacturing defects are a separate BD quality issue.
Report Contents
| Section | What You'll Learn |
|---|---|
| The Device | What Stiletto is, how SlipStream works, why guidewire-free matters |
| The Market | Market size, buyer personas, top procedure markets |
| Competitive Landscape | BD injury rates, failure modes, what MAUDE can and can't tell you |
| Selling the Story | SPIN framework, battle cards, and what NOT to claim |
| Go-to-Market | Target accounts, channels, AI outreach, ScanPath in sales |
| Methodology | Data quality assessment, API usage, limitations, reproducible queries |
Data: FDA MAUDE (2.50M events, 1992-2026). CMS Medicare 2022 procedure volumes. Analysis current as of February 2026. Device linkage at 99.3%. All claims include sample sizes -- see Methodology for data quality details.